Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07447960

LRFN5 and OLFM4 in Schizoaffective Disorder

Conditions: Schizoaffective Disorder

Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Enrollment: 110
Sponsor: Elazığ Mental Health and Diseases Hospital

Location: Elazığ Mental Health and Diseases Hospital Psychiatry Clinic Elâzığ Elâzığ

Summary

Schizoaffective disorder (SAD) is a chronic psychiatric condition characterized by psychotic and mood symptoms. Emerging evidence suggests that Leucine-Rich Repeat and Fibronectin Type-III Domain-Containing Protein 5 (LRFN5) and olfactomedin-4 (OLFM4) may play roles in synaptic organization, neurodevelopment, and neuroinflammation. However, no prior study has investigated these biomarkers in SAD. This cross-sectional case-control study aims to compare peripheral serum levels of LRFN5 and OLFM4 in subjects diagnosed with SAD in remission and healthy control subjects. The study also assessed associations between these biomarkers and clinical symptom severity, global functioning, and systemic inflammation measured by the Aggregate Index of Systemic Inflammation (AISI). The study aimed to investigate convergent synaptic and immunoinflammatory dysregulation in SAD.

Eligibility Criteria

1. For Schizoaffective Disorder (SAD) Group: \*Inclusion Criteria: * Diagnosis of SAD according to DSM-5-TR * Acute manic episode * Medication-free for at least one month prior to admission * Age ≥ 18 years and \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07447960). StuddyBuddy aggregates publicly available trial information.